Sulfaprim Teaching 33

Charting language
Instructed in new medication Sulfaprim and in S/E such as headache, mental depression, aseptic meningitis, tinnitus, apathy, seizures, hallucinations, ataxia, nervousness, fatigue, vertigo, insomnia, thrombophlebitis, nausea, vomiting, diarrhea, abdominal pain, anorexia, stomatitis, pancreatitis, pseudomembranous colitis, toxic nephrosis with oliguria and anuria, crystalluria, hematuria, interstitial nephritis, agranulocytosis, aplastic anemia, megaloblastic anemia, thrombocytopenia, leukopenia, hemolytic anemia, jaundice, hepatic necrosis, arthralgia, myalgia, muscle weakness, pulmonary infiltrates, erythema multiforme, Stevens-Johnson syndrome, generalized skin eruption, toxic epidermal necrolysis, exfoliative dermatitis, photosensitivity, urticaria, pruritus, hypersensitivity reactions, serum sickness, drug fever and anaphylaxis.

Reviewed November 2017

Reviewed for general reference only. Adapt to your patient, agency policy, and scope of practice.